- Gregory Hamilton has a proven track-record of successfully leading U.S. diagnostics companies
- Appointment underscores Epigenomics’ ambitions and goals in the U.S. market
- New CEO to join Epigenomics on July 1, 2016
Berlin (Germany) and Germantown, MD (U.S.A.), June 30, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that the Supervisory Board appointed Gregory Hamilton as Chief Executive Officer with effect from July 1, 2016. Mr. Hamilton, who has held senior management positions in the U.S. molecular diagnostics industry, will succeed Dr. Thomas Taapken.
Mr. Hamilton, (46), has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. Prior to joining Epigenomics, Mr. Hamilton was Chief Executive Officer & Director of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He has been responsible for multiple FDA-cleared products including a Human Papilloma Virus (HPV) High Risk Screening assay and the first ever cleared HPV genotyping assay. Mr. Hamilton received his MBA from the University of Chicago and his Bachelor of Science in Finance from Purdue University.
Heino von Prondzynski, Chairman of the Supervisory Board, stated: “The Supervisory Board conducted a thorough search process and is convinced that Mr. Hamilton is the right choice for Epigenomics at this time. Mr. Hamilton has an extremely strong track record of accomplishments in the U.S. molecular diagnostic industry and has been responsible for a number of innovative diagnostic products, which makes him an ideal appointment for driving the commercialization of our blood-based colorectal cancer test Epi proColon®. We are convinced that Epigenomics will strongly benefit from Mr. Hamilton’s outstanding industry experience and network.”
“I am excited about the opportunity to join Epigenomics and to contribute to the company’s future success,” said Mr. Hamilton. “Epigenomics’ blood-based cancer tests have the potential to radically improve cancer detection worldwide. Together with my colleagues at Epigenomics, I will make every effort to let this vision come true – for the benefit of patients and our shareholders.”
Dr. Thomas Taapken, who has served in the dual role of CEO and CFO since 2012, will leave the company with effect of today. “The Supervisory Board would like to express its great appreciation for Dr. Taapken’s outstanding contributions to the development of the company”, added Heino von Prondzynski. “Under his leadership, Epigenomics has evolved into a product-oriented molecular diagnostics company with excellent prospects in the field of blood-based cancer detection. The Supervisory Board wishes Dr. Taapken all the best for the future.”
The vacant CFO position will be filled shortly.
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.
For more information, visit www.epigenomics.com.
Contact Epigenomics AG
Vice President Corporate Communication & Investor Relations
Phone +49 (0) 30 24345 386
For U.S. press inquiries:
Tel: (917) 837-5866
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.